| Pharmaceutical Information |
| Drug Name |
Alogliptin benzoate |
| Drug ID |
BADD_D00080 |
| Description |
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. |
| Indications and Usage |
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| Marketing Status |
approved |
| ATC Code |
A10BH04 |
| DrugBank ID |
DB06203
|
| KEGG ID |
D06553
|
| MeSH ID |
C520853
|
| PubChem ID |
16088021
|
| TTD Drug ID |
D0NJ5H
|
| NDC Product Code |
14445-016; 14501-0024; 42765-057; 69037-0024; 66039-924 |
| UNII |
EEN99869SC
|
| Synonyms |
alogliptin | 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile | nesina | SYR 322 | SYR322 | SYR-322 |
|
| Chemical Information |
| Molecular Formula |
C25H27N5O4 |
| CAS Registry Number |
850649-62-6 |
| SMILES |
CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N.C1=CC=C(C=C1)C(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
